Outcomes-based pricing as a tool to ensure access to novel but expensive biopharmaceuticals

Annals of Internal Medicine

Volumn 166, Issue 3, 2017, Pages 219-220

  Blumenthal, Daniel M ^a   Goldman, Dana P ^b   Jena, Anupam B ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE 9; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN;

ADVERSE OUTCOME; BUDGET; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; FAMILIAL HYPERLIPEMIA; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL READMISSION; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; LONG TERM CARE; MANAGED CARE; MAXIMUM TOLERATED DOSE; META ANALYSIS (TOPIC); NOTE; OUTCOME BASED PRICING; PHARMACEUTICAL CARE; POLYPHARMACY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ECONOMICS; FEE; OUTCOME ASSESSMENT; PHARMACEUTICS; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BIOPHARMACEUTICS; DRUG COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRESCRIPTION FEES; PROPROTEIN CONVERTASE 9; UNITED STATES;

EID: 85020740108     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1847     Document Type: Note

References (10)

1. Jena AB, Blumenthal DM, Stevens W, Chou J.W., Ton TG, Goldman DP. Value of improved lipid control in patients at high risk for adverse cardiac events. Am J Manag Care. 2016; 22:e199-207. [PMID: 27355907]
2. Navarese EP, Kolodziejczak M, Schulze V., Gurbel PA, Tantry U, Lin Y, et al Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015; 163:40-51. [PMID: 25915661] doi:10.7326/M14-2957
3. Everett BM, Smith RJ, Hiatt WR Reducing LDL with PCSK9 inhibitors - the clinical benefit of lipid drugs. N Engl J Med. 2015; 373: 1588-91. [PMID: 26444323] doi:10.1056/NEJMp1508120
4. Kazi DS, Moran AE, Coxson P.G., Penko J., Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016; 316:743-53. [PMID: 27533159] doi:10.1001/jama.2016.11004
5. Shrank W, Lotvin A, Singh S., Brennan T. In the debate about cost and efficacy, PCSK9 inhibitors may be the biggest challenge yet. Health Affairs Blog. 17 February 2015. Accessed at http://healthaffairs.org/blog/2015/02/17/in-the-debate-about-cost-and-efficacy-pcsk9-inhibitors-may-be-the-biggest-challenge-yet on 1 November 2016.
6. Humer C, Pierson R. Express Scripts sees slow 2016 sales for new cholesterol drugs. Thomson Reuters. 12 February 2016. Accessed at www.reuters.com/article/us-express-scr-cholesteroldrugs-idUSKCN0VL2AX on 1 November 2016.
7. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B., Herholz H, Wendykowska K, et al Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010; 10:153. [PMID: 20529296] doi: 10.1186/1472-6963-10-153
8. Khera AV, Won HH, Peloso G.M., Lawson KS, Bartz TM, Deng X, et al Diagnostic yield and clinical utility of sequencing familial hyper-cholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016; 67:2578-89. [PMID: 27050191] doi:10.1016/j.jacc.2016.03.520
9. Neumann PJ, Chambers JD, Simon F, Meckley LM Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011; 30:2329-37. [PMID: 22147861] doi:10.1377/hlthaff.2010.1147
10. Weisman R. Harvard Pilgrim strikes "pay-for-performance" deal for cholesterol drug. The Boston Globe. 8 November 2015.